Relationship of Lipoproteins to Cardiovascular Events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Trial.

Department of Medicine, Duke University Medical Center, Durham, NC. Electronic address: .
Journal of the American College of Cardiology (Impact Factor: 15.34). 07/2013; DOI: 10.1016/j.jacc.2013.07.023
Source: PubMed

ABSTRACT In this secondary analysis of the AIM-HIGH trial, the objectives were to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes.
During 3-year follow-up in 3,414 patients with established CV disease and low HDL-C, combined niacin + LDL-lowering therapy did not reduce CV events versus LDL-lowering therapy alone.
Subjects taking simvastatin ± ezetimibe were randomized to extended-release (ER) niacin 1500-2000 mg or minimal immediate-release niacin (<150 mg) as placebo at bedtime. LDL-C in both groups was maintained from 40 to 80 mg/dL. Hazard ratios (HR) were estimated by Cox proportional hazards for relationships between lipoproteins and the composite endpoint of CV death, myocardial infarction, acute coronary syndrome, ischemic stroke, or symptom-driven revascularization.
CV outcomes were not associated with ER niacin in any baseline lipoprotein tertile. In a subset of patients in both the highest triglyceride (≥198 mg/dl) and lowest HDL-C (<33 mg/dl) tertiles, ER niacin showed a trend toward benefit (HR=0.74, p=0.073). In-trial LDL-C, nonHDL-C, and TC/HDL-C ratio were positively associated with CV events in the control group, but these relationships were absent in the ER niacin group.
Baseline lipoprotein tertiles did not predict differential benefit or harm with ER niacin added to LDL-lowering therapy, but a small dyslipidemic subgroup may benefit. ER niacin attenuated expected relationships of lipoprotein risk factors with CV events, raising the possibility that nonlipoprotein actions of niacin could impact risk.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The metabolic syndrome (MetS) and chronic kidney disease are global health issues. The MetS induces hypertension (HTN) and commonly results in renal damage. The optimal therapy for HTN in the MetS is unknown. Thiazide diuretics are first line therapy; however, these drugs may have untoward effects. This study investigated the effects of azilsartan (AZL), chlorthalidone (CLTD), and the combination (AZL + CLTD) on blood pressure and renal injury in a rodent model with features of the MetS. Dahl salt-sensitive (Dahl S) rats were fed high-fat (36% fat) high-salt (4% NaCl) diet. Groups were then treated with vehicle, AZL (3 mg/kg/day), CLTD (5 mg/kg/day) or AZL+CLTD. Mean arterial pressure (MAP) was recorded continuously by telemetry. After 26 days, rats were humanely killed and kidneys were harvested for histology. Both AZL and CLTD attenuated the rise in blood pressure compared to vehicle, and the combination further reduced blood pressure compared to CLTD alone. All treatments reduced proteinuria and albuminuria. Only groups treated with AZL prevented nephrinuria. Nephrinuria was 57% lower, and proteinuria was 47% lower with combination therapy compared to AZL alone. All treatments reduced the number of inflammatory cells in the kidney. In conclusion, in our model, AZL and CLTD lower blood pressure and exhibit renal protective effects. AZL treatment offers additional protection as evidenced by lower nephrinuria and plasma MCP-1. Combination therapy afforded the greatest protective effects and may be the best choice for hypertensive therapy in the MetS.This article is protected by copyright. All rights reserved.
    Clinical and Experimental Pharmacology and Physiology 05/2014; · 2.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Various organizations and agencies have issued recommendations for the management of dyslipidemia. While many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) ASCVD risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol — non-high-density lipoprotein cholesterol (non-HDL-C) and low-density lipoprotein cholesterol (LDL-C) — as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia.
    Journal of Clinical Lipidology 09/2014; · 3.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leukocyte myeloperoxidase (MPO) is a major player in the pathogenesis of various chronic diseases including atherosclerosis. This study proposes the novel concept that niacin, through reactive oxygen species (ROS)-mediated signaling, decreases neutrophil MPO release and its activity, protects apolipoprotein-AI (apo-AI) modification and improves HDL function.
    Atherosclerosis 06/2014; 235(2):554-561. · 3.71 Impact Factor